论文部分内容阅读
[目的]观察Gravrs甲亢(GD)诊断和口服抗甲状腺药治疗过程sTSH变化,研究其在GD诊断、指导治疗、判断预后及复发的临床意义。[方法]GD患者108例,均选用ATD治疗,治疗初3个月,每2~4周测定FT3、FT4、STSH,之后每8~12周测定1次,停药后3个月、半年、1年各复查1次。[结果]GD亚临床阶段、初发及复发早期sTSH均低于正常,ATD治疗后sTSH恢复正常时间明显落后FT3、FT4恢复正常时间,sTSH未恢复正常值就停药的GD患者复发率明显增高。[结论]sTSH是GD诊断、指导治疗、判断预后及复发的良好指标。
[Objective] To observe the changes of sTSH in the diagnosis of Gravrs hyperthyroidism (GD) and oral anti-thyroid drugs and to study its clinical significance in diagnosis, guiding treatment, prognosis and recurrence of GD. [Methods] A total of 108 patients with GD were enrolled in this study. All patients were treated with ATD for the first 3 months after treatment. FT3, FT4 and STSH were measured every 2 to 4 weeks, then every 8 to 12 weeks, once every 3 to 6 months, 1 review each time. [Results] The sub-clinical stage of GD, sTSH in primary and early relapse were both lower than normal. The recovery time of sTSH after ATD treatment was significantly lower than that of FT3 and FT4, and the relapse rate of GD patients with sTSH not recovering normal was significantly higher . [Conclusion] sTSH is a good indicator of GD diagnosis, guide treatment, prognosis and recurrence.